Abstract
Purpose
Fatty acid-binding protein 5 (FABP5), a transport protein for lipophilic molecules, has been proposed as protein marker in prostate cancer (PCa). The role of FABP5 gene expression is merely unknown.
Methods
In two cohorts of PCa patients who underwent radical prostatectomy (n = 40 and n = 57) and one cohort of patients treated with palliative transurethral resection of the prostate (pTUR-P; n = 50) FABP5 mRNA expression was analyzed with qRT-PCR. Expression was correlated with clinical parameters. BPH tissue samples served as control. To independently validate findings on FABP5 expression, three microarray and sequencing datasets were reanalyzed (MSKCC 2010 n = 216; TCGA 2015 n = 333; mCRPC, Nature Medicine 2016 n = 114). FABP5 expression was correlated with ERG-fusion status, TCGA subtypes, cancer driver mutations and the expression of druggable downstream pathway components.
Results
FABP5 was overexpressed in PCa compared to BPH in the cohorts analyzed by qRT-PCR (radical prostatectomy p = 0.003, p = 0.010; pTUR-P p = 0.002). FABP5 expression was independent of T stage, Gleason Score, nodal status and PSA level. FABP5 overexpression was associated with the absence of TMPRSS2:ERG fusion (p < 0.001 in TCGA and MSKCC). Correlation with TCGA subtypes revealed FABP5 overexpression to be associated with SPOP and FOXA1 mutations. FABP5 was positively correlated with potential drug targets located downstream of FABP5 in the PPAR-signaling pathway.
Conclusion
FABP5 overexpression is frequent in PCa, but seems to be restricted to TMPRESS2:ERG fusion-negative tumors and is associated with SPOP and FOXA1 mutations. FABP5 overexpression appears to be indicative for increased activity in PPAR signaling, which is potentially druggable.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00345-019-02651-8/MediaObjects/345_2019_2651_Fig1_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00345-019-02651-8/MediaObjects/345_2019_2651_Fig2_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00345-019-02651-8/MediaObjects/345_2019_2651_Fig3_HTML.png)
Similar content being viewed by others
Abbreviations
- PCa:
-
Prostate cancer
- mCRPC:
-
Metastatic castration-resistant prostate cancer
- IHC:
-
Immunohistochemistry
- IQR:
-
Interquartile range
- BPH:
-
Benign prostatic hyperplasia
- pTUR-P:
-
Palliative transurethral resection of the prostate
References
Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46(4):765–781
Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS et al (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18(1):11–22
Cancer Genome Atlas Research Network (2015) The molecular taxonomy of primary prostate cancer. Cell 163(4):1011–1025
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun X-W et al (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748):644–648
Squire JA (2009) TMPRSS2-ERG and PTEN loss in prostate cancer. Nat Genet 41(5):509–510
Pentyala S, Whyard T, Pentyala S, Muller J, Pfail J, Parmar S et al (2016) Prostate cancer markers: an update. Biomed Rep 4(3):263–268
Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J et al (2017) Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol 72(4):544–554
Beltran H, Wyatt AW, Chedgy EC, Donoghue A, Annala M, Warner EW et al (2017) Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy. Clin Cancer Res 23(22):6802–6811
Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M et al (2017) Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy. JAMA Oncol 3(12):1663–1672
Adamson J, Morgan EA, Beesley C, Mei Y, Foster CS, Fujii H et al (2003) High-level expression of cutaneous fatty acid-binding protein in prostatic carcinomas and its effect on tumorigenicity. Oncogene 22(18):2739–2749
Morgan EA, Forootan SS, Adamson J, Foster CS, Fujii H, Igarashi M et al (2008) Expression of cutaneous fatty acid-binding protein (C-FABP) in prostate cancer: potential prognostic marker and target for tumourigenicity-suppression. Int J Oncol 32(4):767–775
Forootan FS, Forootan SS, Malki MI, Chen D, Li G, Lin K et al (2014) The expression of C-FABP and PPARγ and their prognostic significance in prostate cancer. Int J Oncol 44(1):265–275
Pang J, Liu W-P, Liu X-P, Li L-Y, Fang Y-Q, Sun Q-P et al (2010) Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis. J Proteome Res 9(1):216–226
Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J et al (2016) Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med 22(3):298–305
Myers JS, von Lersner AK, Sang Q-XA (2016) Proteomic upregulation of fatty acid synthase and fatty acid binding protein 5 and identification of cancer- and race-specific pathway associations in human prostate cancer tissues. J Cancer 7(11):1452–1464
Eckstein M, Wirtz RM, Pfannstil C, Wach S, Stoehr R, Breyer J et al (2018) A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. Oncotarget 9(19):15001–15014
Tyekucheva S, Martin NE, Stack EC, Wei W, Vathipadiekal V, Waldron L et al (2015) Comparing platforms for messenger RNA expression profiling of archival formalin-fixed. Paraffin-embedded tissues. J Mol Diagn 17(4):374–381
Huang K-C, Dolph M, Donnelly B, Bismar TA (2014) ERG expression is associated with increased risk of biochemical relapse following radical prostatectomy in early onset prostate cancer. Clin Transl Oncol 16(11):973–979
Berg KD, Vainer B, Thomsen FB, Røder MA, Gerds TA, Toft BG et al (2014) ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer. Eur Urol 66(5):851–860
Senga S, Kawaguchi K, Kobayashi N, Ando A, Fujii H (2018) A novel fatty acid-binding protein 5-estrogen-related receptor α signaling pathway promotes cell growth and energy metabolism in prostate cancer cells. Oncotarget 9(60):31753–31770
Blattner M, Lee DJ, O’Reilly C, Park K, MacDonald TY, Khani F et al (2014) SPOP mutations in prostate cancer across demographically diverse patient cohorts. Neoplasia 16(1):14–20
Alshalalfa M, Bismar TA, Alhajj R (2012) Detecting cancer outlier genes with potential rearrangement using gene expression data and biological networks. Adv Bioinform 2012:373506
Morgan E, Kannan-Thulasiraman P, Noy N (2010) Involvement of fatty acid binding protein 5 and PPARβ/δ in prostate cancer cell growth. PPAR Res. https://doi.org/10.1155/2010/234629
Pan L, Xiao H, Liao R, Chen Q, Peng C, Zhang Y et al (2018) Fatty acid binding protein 5 promotes tumor angiogenesis and activates the IL6/STAT3/VEGFA pathway in hepatocellular carcinoma. Biomed Pharmacother 1(106):68–76
Al-Jameel W, Gou X, Forootan SS, Al Fayi MS, Rudland PS, Forootan FS et al (2017) Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5. Oncotarget 8(19):31041–31056
Forootan SS, Bao ZZ, Forootan FS, Kamalian L, Zhang Y, Bee A et al (2010) Atelocollagen-delivered siRNA targeting the FABP5 gene as an experimental therapy for prostate cancer in mouse xenografts. Int J Oncol 36(1):69–76
Takanashi K, Suda M, Matsumoto K, Ishihara C, Toda K, Kawaguchi K et al (2017) Epicatechin oligomers longer than trimers have anti-cancer activities, but not the catechin counterparts. Sci Rep 7(1):7791
Senga S, Kobayashi N, Kawaguchi K, Ando A, Fujii H (2018) Fatty acid-binding protein 5 (FABP5) promotes lipolysis of lipid droplets, de novo fatty acid (FA) synthesis and activation of nuclear factor-kappa B (NF-κB) signaling in cancer cells. Biochim Biophys Acta Mol Cell Biol Lipids 1863(9):1057–1067
Fujita K, Kume H, Matsuzaki K, Kawashima A, Ujike T, Nagahara A et al (2017) Proteomic analysis of urinary extracellular vesicles from high Gleason score prostate cancer. Sci Rep 17(7):42961
Worst TS, von Hardenberg J, Gross JC, Erben P, Schnölzer M, Hausser I et al (2017) Database-augmented mass spectrometry analysis of exosomes identifies claudin 3 as a putative prostate cancer biomarker. Mol Cell Proteomics 16(6):998–1008
Acknowledgements
The project was funded by the B. Braun Stiftung (Melsungen, Germany). TSW was supported by a Ferdinand Eisenberger scholarship of the German Society of Urology.
Funding
This work was funded by the B. Braun Foundation (Melsungen, Germany). The funding sponsor had no role in the design of the study, in the collection, analysis or interpretation of the data, in the preparation of the manuscript and in the decision to publish the results.
Author information
Authors and Affiliations
Contributions
KN: qRT-PCR experiments, data analysis, data collection, manuscript writing. PE: data analysis, manuscript writing. FW: qRT-PCR experiments, data analysis, data collection. AA: qRT-PCR experiments, data analysis. C-AW: tissue fixation, embedding, sectioning, staining and image acquisition. MG: tissue fixation, embedding, sectioning, staining and image acquisition. SW: qRT-PCR experiments. PN: project planning, manuscript writing. MB: project planning. MSM: project planning. JH: scientific advice, manuscript writing. TSW: project development, data collection, data analysis, manuscript writing.
Corresponding author
Ethics declarations
Conflict of interest
All authors declare no conflict of interest.
Ethical approval
The study includes data and tissue from human participants in a retrospective study (ethics approval 2013-845R-MA, 2014-592 N-MA).
Informed consent
All patients gave informed consent for participation. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Nitschke, K., Erben, P., Waldbillig, F. et al. Clinical relevance of gene expression in localized and metastatic prostate cancer exemplified by FABP5. World J Urol 38, 637–645 (2020). https://doi.org/10.1007/s00345-019-02651-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-019-02651-8